Futu News reported on May 29 that the three major indices of Hong Kong stocks fell collectively. At the close, the Hang Seng Index fell 1.83%, the Science Index fell 2.32%, and the National Index fell 1.92%.
By the close, Hong Kong stocks had risen 596, down 1,339, and closed at 1,081.
The specific industry performance is as follows:
On the sector side, TechNet stocks generally fell, Meituan fell more than 5%, Ali and Jingdong fell more than 3%, Kuaishou, Baidu, Bilibili, and Tencent fell more than 2%, Xiaomi fell nearly 2%, and NetEase fell slightly.
Biotech stocks weakened. Corning Jerry Pharmaceuticals fell nearly 45%, Kangfang Biotech fell more than 7%, Pharmaceutical Biotech fell nearly 3%, and Kingsley Biotech fell more than 2%.
Auto stock trends were divided. BYD shares rose more than 5%, Xiaopeng and Great Wall rose slightly; Brilliance fell nearly 4%, NIO fell more than 2%, and Geely fell more than 1%.
Pharmaceutical stocks fell one after another, with Shiyao Group falling nearly 4%, Cinda Biotech and China Biopharmaceuticals falling nearly 3%, and Kangzhe Pharmaceutical falling more than 2%.
Many travel and tourism stocks declined. Ctrip fell more than 3%, Tongcheng Travel fell nearly 2%, and China Central China declined by more than 1%.
On the other side, military stocks and pork concept stocks fell higher. Mobile game stocks, restaurant stocks, domestic housing stocks, and property management stocks fell one after another; automobile stocks led lithium battery stocks and Tesla concept stocks to rise sharply, coal stocks continued to be active, and China Coal Energy continued to hit new highs.
In terms of individual stocks,$BYD COMPANY (01211.HK)$It increased by more than 5%, released fifth-generation DM technology, and the pricing of the two new cars exceeded expectations.
$ALPHAMAB-B (09966.HK)$It fell nearly 45%, and the KN046-303 clinical trial failed. Last year, it was mired in a storm of insider leaks.
$CENTRAL NEW EGY (01735.HK)$It increased by more than 4%, signed a cooperation framework agreement with Sunshine Power, and strengthened the strategic cooperative relationship between the two sides.
$CHINA COAL (01898.HK)$With an increase of more than 3%, the peak electricity consumption season is approaching, and spot coal prices are expected to continue to strengthen.
$CHINA RUYI (00136.HK)$With an increase of more than 3%, the acquisition of Youai Mutual Entertainment is expected to expand its gaming footprint and create collaborations with Wanda Film's various businesses.
Today's top 10 Hong Kong stock turnover
Hong Kong Stock Connect Capital
On the Hong Kong Stock Connect side, today's net inflow of Hong Kong Stock Connect (southbound) was HK$6.774 billion.
Agency Perspectives
UBS: Giving Tencent Holdings a “buy” rating, target price of HK$480
UBS released a research report stating that it reaffirms its right$TENCENT (00700.HK)$The positive view is that the management clearly set out the future growth drivers of the Group, including the recent successful launch of the mobile game “Dungeons and Warriors” and its Supercell games are recovering, as well as medium-term drivers such as live e-commerce, artificial intelligence, and investment. According to the report, the Group's firm commitment to share repurchases, emphasis on shareholder returns and internal rate of return (IRR), etc. will all support the valuation; a “buy” rating will be given, with a target price of HK$480.
Lyon: Maintaining Ali Health's “Buy” Rating, Target Price Raised to HK$4.5
Lyon released a research report saying, maintain$ALI HEALTH (00241.HK)$The “Buy” rating is more optimistic about growth and profit prospects. The revenue forecast for the current fiscal year and the next fiscal year was raised by 6% and 8% each, and the adjusted net profit forecast for the same period was raised by 9% each. The target price was raised from HK$4.1 to HK$4.5. According to the report, the company's performance for the second half of fiscal year 2024 far surpassed the bank's expectations under a high base, and the increase in efficiency significantly boosted profit margins. Alibaba Health is more proactive in expanding its own business, while attracting all merchants to increase advertising investment through exclusive supply, new products and operational efforts.
Nomura: Raised Kuaishou-W target price to HK$63, first quarter profit exceeded expectations
Nomura released a research report saying, based on$KUAISHOU-W (01024.HK)$According to the latest performance guidelines, the company's profit forecast for this year was raised by 6%, and the target price was raised from HK$58.5 to HK$63. According to the report, the company's profit for the first quarter was 4.4 billion yuan, higher than market expectations of 3.2 billion yuan, mainly due to higher profit margins. Driven by operating leverage, the non-GAAP operating margin improved 12 percentage points year over year to 12.7%. The 17% year-on-year increase in first-quarter revenue is in line with expectations.
Edit/Cynthia